VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

International Journal of Medical Sciences

Volumn 9, Issue 10, 2012, Pages 833-837

  Tamura, Takao ^a,b   Kuwahara, Akiko ^b,c   Yamamori, Motohiro ^b,c   Nishiguchi, Kohshi ^b,d   Nakamura, Tsutomu ^b   Okuno, Tatsuya ^b   Miki, Ikuya ^b   Manabe, Yuki ^e   Sakaeda, Toshiyuki ^b,e  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal squamous cell carcinoma; Late toxicity; Prognosis; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; FLUOROURACIL; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; JAPANESE; LONG TERM SURVIVAL; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OROPHARYNX CANCER; OVERALL SURVIVAL; RADIATION DOSE; SUDDEN DEATH; SURVIVAL RATE; SURVIVAL TIME; TONGUE CANCER; TREATMENT RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; LATE TOXICITY; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR.;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869050797     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.4914     Document Type: Article

References (34)

1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281: 1623-1627.
2. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 1992; 326: 1593-1598.
3. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J. Clin. Oncol. 1997; 15: 277-284.
4. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996; 276: 637-639.
5. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J. Clin. Oncol. 1999; 17: 2915-2921.
6. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br. J. Cancer. 2003; 88: 18-24.
7. Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn. J. Clin. Oncol. 2005; 35: 316-323.
8. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J. Clin. Oncol. 2003; 21: 2697-2702.
9. Kumekawa Y, Kaneko K, Ito H, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J. Gastroenterol. 2006; 41: 425-432.
10. Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75: 122-128.
11. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J. Clin. Oncol. 2005; 23: 2310-2317.
12. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 2007; 25: 1160-1168.
13. Sakaeda T, Yamamori M, Kuwahara A, et al. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv. Drug Deliv. Rev. 2009; 61: 388-401.
14. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther. Drug Monit. 2005; 27: 369-374.
15. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am. J. Clin. Oncol. 2007; 30: 252-257.
16. Sakaeda T, Yamamori M, Kuwahara A, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther. Drug Monit. 2008; 30: 497-503.
17. Kuwahara A, Yamamori M, Nishiguchi K, et al. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int. J. Med. Sci. 2009; 6: 305-311.
18. Kuwahara A, Yamamori M, Nishiguchi K, et al. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int. J. Med. Sci. 2010; 7: 48-54.
19. Kuwahara A, Yamamori M, Fujita M, et al. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2010; 29: 100.
20. Hansen TF, Jakobsen A. Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics. 2011; 12: 1681-1693.
21. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 2009; 8: 2496-2508.
22. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin. Cancer Res. 2009; 15: 5297-5302.
23. Cao C, Fang JJ, Ying T, et al. Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis. Arch. Med. Res. 2010; 41: 548-557.
24. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983-985.
25. Criscuolo GR, Merrill MJ, Oldfield EH. Further characterization of malignant glioma-derived vascular permeability factor. J. Neurosurg. 1988; 69: 254-262.
26. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989; 161: 851-858.
27. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 1989; 84: 1470-1478.
28. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246: 1306-1309.
29. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246: 1309-1312.
30. Kajdaniuk D, Marek B, Foltyn W, et al. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol. Pol. 2011; 62: 444-455.
31. Kajdaniuk D, Marek B, Foltyn W, et al. Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology. Endokrynol. Pol. 2011; 62: 456-464.
32. Tugues S, Koch S, Gualandi L, Li X, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol. Aspects Med. 2011; 32: 88-111.
33. Carver JR, Shapiro CL, Ng A, et al; ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 2007; 25: 3991-4008.
34. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J. Clin. Oncol. 2009; 27: 2328-2338.